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Entering the Age of the New Genetics 
with Eyes Wide Open 
Sharon S. Ayabe, S.Y. Tan MD, JD 
A concerted international effort currently is being made to 
localize human genes and to identify their role in specific 
diseases. This will enable physicians to test for a broader range 
of genetic characteristics and to manipulate human somatic and 
germ-line cells. With this new age of genetics comes a host of 
ethical issues and questions. 
Introduction 
Richard is 2 years old and his uncle just died from Huntington's 
disease. His parents read in Reader's Digest that a simple blood 
test could determine if he, too, will develop Huntington's 
disease. 
Malia, 35, is 10 weeks pregnant. She is requesting "genetic 
testing" on her fetus because she and her husband want to have 
"the perfect family." 
Susie is 21 and from Cleveland; she has been dating your 
patient Kimo. They recently visited her family on the Mainland, 
including a few cousins with cystic fibrosis and now Kimo is 
concerned that Susie may be a carrier. Today she presents at your 
office asking to be screened for the cystic fibrosis gene. 
Any one of these patients may present at the physician's office 
with questions concerning medical genetics. Questions which 
hitherto had been prefaced with if and when have now burst forth 
as the issues for the here and now. Ready or not, primary care 
physicians will move to the frontlines of this genetic revolution 
as they manage their patients' requests and needs for genetic 
services. 
Genetic Testing 
Genetic screening is generally used in two arenas: 1) testing of 
presymptomatic individuals for medical treatment, and 2) test-
ing of couples for reproductive decision making. Ideally, in the 
former case, people learn they have a genetic disorder and then 
receive effective treatment through conventional medical or 
genetic therapy. And in the latter, couples can decide whether 
they will risk conception, terminate a pregnancy, or prepare for 
the birth of an affected child. 
Why Test if There is No Cure? 
Almost everyone agrees that presymptomatic testing is appro-
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priate when an intervention is efficacious when started before 
symptoms appear. 1 But is testing beneficial when no cure for the 
disease is available? 
For example, Huntington's chorea is an autosomal-dominant 
disease that usually cannot be clinically diagnosed until the 
fourth or fifth decade oflife. But it can be genetically diagnosed 
in an asymptomatic individual. Unfortunately, no cure exists for 
this mentally and physically debilitating condition yet. Indi-
viduals have approached their physicians requesting testing for 
themselves or their offspring hoping that they are not at risk. 
Usually they are unaware of the emotional and social harm 
stemming from a positive test result. 
Some studies suggest that as many as one in 10 patients who 
test positive for the Huntington's disease mutation never make 
a full emotional recovery.2 Even with professional counseling, 
a few have had to be hospitalized for severe depression and some 
have even committed suicide. 
Individuals who test positive may be stigmatized. In the past, 
large screening efforts were made for sickle cell traits, Tay-Sachs 
disease, and Alpha1-antitrypsin deficiency which led to adverse 
psychological consequences for parents of affected children. 
They felt afraid, worried, and anxious. 3 Carriers of the sickle cell 
trait were stigmatized as being undesirable marriage partners 
and were socially ostracized.4 Additionally, children who test 
positive may become scapegoats who are abused because they 
remind their parents of their own unacceptable traits.5 
Similarly, Dr Bruce Ponder, who has been seeking the genetic 
marker for breast cancer at Cambridge University, worries that 
patients who test positive for cancer might actually increase 
their cancer mortality. Positive test results, by triggering depres-
sion, may actually worsen a patient's chances of survivai.2 
Emotional stress, disturbed sleep patterns, and decreased appe-
tite may all contribute to a diminished immune response and 
hasten disease progression. 
On the other hand, a large study conducted in Canada sug-
gested that knowledge of disease status can actually improve the 
quality of life. After they requested testing for Huntington's 
disease and learned 'of their risk, many patients reported im-
proved well-being, less anxiety, less depression, and general 
improvement in their psychological status than when they were 
living with uncertainty.6 
Clearly, for some people living with ambiguity is worse than 
bad news. For these individuals a case can be made for testing 
even if there is no cure. For others, ignorance is preferable to 
knowledge of impending disease. Those who request testing 
will need counseling and education regarding how the test result 
might affect them. 
Primary care physicians are familiar with patients requesting 
a variety of diagnostic tests and medical therapies. They know 
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their patients well, and they are skilled at helping them under-
stand the risks and benefits of medical services. When neces-
sary, they do not hesitate to discourage certain patient requests 
believing that more harm than good would result. These 
patient-care skills, coupled with an understanding of the new 
genetics, will allow the primary care physician to assume the 
lead advisory role with regard to genetic testing. 
Will Genetic Testing Enforce Fatalistic Attitudes? 
Some critics have condemned the overemphasis, particularly in 
the media, on genetic causes of behavior and disease. They 
speak of the geneticization of society and argue that 
over-expenditure of resources on genetic research will be at the 
expense of basic social needs, such as food, shelter, and routine 
prenatal care.7 Over-genetization can adversely affect individu-
als and frustrate the physicians who work with them. 
Both genetic predispositions and environmental influences 
bear on a patient's health. Yet some fatalistic patients blame 
their lack of health on everything except their poor life-style 
choices. Armed with knowledge of genetic markers for diseases 
like alcoholism and obesity, these patients will deny responsibil-
ity for their conditions all the more and may stubbornly refuse 
to participate in their health care. 
If patients test negative for breast cancer, would they conclude 
that they no longer need routine breast examinations? If a patient 
were determined to be susceptible to coronary heart disease 
because of his or her genes, might this cause him or her to ignore 
dietary and exercise advice? To the extent that genes are seen as 
more important than the environment, our actions may be 
viewed as genetically determined, rather than as a result of free 
will. For example, some criminals have attempted to use theXYY 
defense arguing that their genetic composition predisposed them 
to criminal activities beyond their control. The XYY defense 
generally has been rejected in court. 8 
The focus on genetic disease should not pull society away 
from personal responsibility. Fortunately, most patients under-
stand how life-style choices affect their health. When reporting 
results of genetic screening to their patients, physicians must 
reinforce the notion that genetic predisposition is but one deter-
minant of disease and emphasize suggestions for minimizing 
disease expression. 
Will Defective Genes Invite Discrimination? 
Predictive genetic testing reveals asymptomatic conditions that 
can manifest themselves later in life or can remain unveiled. 
This information is not only of interest to patients and their 
physicians but also to their prospective employers and insurers. 
A recent article described 41 cases of discrimination against 
otherwise healthy people based solely on their genetic risk. In 
most cases, the victims were refused health or life insurance. 
Some were refused jobs; others were banned from adopting 
children.2 According to a 1991 survey conducted by the Con-
gressional Office of Technology Assessment, only 12 of 330 
Fortune 500 companies reported they were conducting genetic 
monitoring or screening. Roughly half of these executives 
thought genetic monitoring or screening would be acceptable, 
either for the benefit of the employee or the employer.9 
The Americans with Disabilities Act (ADA) ensures that 
handicapped individuals are not discriminated against in the job 
market. Applicants are considered qualified if they are able to 
meet all the program's requirements in spite of their handicap. 
Additionally, the employer could be required to provide reason-
-
able accommodations to make employment possible. However, 
the Equal Employment Opportunity Commission, the federal 
agency for enforcing the ADA, has stated that "physical or 
mental impairment" does not include "characteristic predispo-
sition to illness or disease.' ' 10 This narrow construct could mean 
healthy people can be denied opportunities based on conditions 
to which they are predisposed, while the symptomatic are 
protected from discrimination. This is unfair and irrational. 
Consider insurance companies. Currently insurers may be 
satisfied with gleaning information from genetic tests already 
performed and will undoubtedly be gathering this information 
from applicants through questionnaires or medical records. 
Already children with genetic disorders may lose their health 
insurance when they become adults; this potential loss has often 
prompted geneticists to avoid seeking a definitive diagnosis.7 
Thus far, state insurance commissions in the United States have 
placed genetic information in the same category as other types 
of medical information that insurers could legally require as a 
condition of insurance.7 However, legislation has been intro-
duced in several states to allow people to keep genetic informa-
tion, including family histories, from insurers.6 Such legislation 
would help protect people from discrimination, but may over-
burden insurance companies, especially life insurance compa-
nies, in their underwriting practices. Insurers have argued that if 
they cannot access an applicant's genetic profile they will be at 
an unfair disadvantage-some individuals, on learning that they 
could develop a serious condition, will buy large amounts of 
insurance.10 
Patients with genetic predispositions to disease must have the 
right to pursue happiness through financial stability and produc-
tivity. Employers and insurance companies have the right to 
make a profit. In the new genetics, a victory for society should 
not be at the expense of any of these players. Insurance compa-
nies should provide coverage for those with genetic risks, with 
such policyholders paying modestly higher premiums for their 
coverage. Employers should hire these people and when reason-
able they should accommodate their predispositions. For ex-
ample, if current or prospective employees test positive for 
Alpha1-antitrypsin deficiency, reasonable accommodations ought 
to be made for them to avoid contact with noxious inhalants. 
Should Carriers of Serious Genetic Disorders Burden Soci-
ety with Their Offspring? 
In a 1990 general population survey, 39% of the respondents 
believed that "every woman who is pregnant should be tested to 
determine if the baby has any serious genetic defects." 
Twenty-two percent thought that, regardless of what they would 
want for themselves, "a woman should have an abortion if the 
baby has a serious genetic defect." Nearly 10% believed a poor 
woman should be required by law to have an abortion rather than 
have the government pay for the child's care. 11 
As health care becomes increasingly rationed, taxpayers could 
resent having to pay for the support of disabled children if their 
births could have been prevented. If a woman undergoes a 
prenatal diagnosis and then decides to carry to term a baby with 
a serious, incurable, and costly problem she may be socially 
scorned. She could, of course, refuse prenatal diagnosis, but she 
would still be considered irresponsible for doing so. But many 
genetic tests contain only crude predictive value. A positive 
result often cannot predict the extent of potential penetrance and 
expression of a defective gene in an individual. A society that 
coerces women into having abortions based on the results of 
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genetic tests will force "throwing out many healthy babies along 
with the bathwater." Private insurance companies in the United 
States have already tried to withhold reimbursement for medical 
care of children with cystic fibrosis who were diagnosed before 
birth and whose parents refused to abort. Thus far, state insur-
ance commissioners have prevented this type of discrimination. 11 
Can a culture that places such high value on a woman's right 
to choose abortion even consider limiting her right to choose 
life? 
What is Normal? 
enough to serve as competent counselors. 15 
Although it is reasonable to assume that geneticists are more 
familiar with all the nuances in their field, it is equally true that 
primary care physicians are more informed about their patients' 
individual and family needs and desires. These physicians can 
familiarize themselves with pertinent issues regarding the new 
genetics. But not every genetics counselor can come to know 
patients and their families with the intimacy their personal 
physicians can. Patients look to their primary care doctors to 
interpret many other laboratory tests and to give appropriate 
advice. Well-informed physicians who understand the limits, 
benefits, and risks of genetic testing should play the central role 
as advocates and advisors for their patients. 
People are special because they possess unique genetic charac-
teristics expressed as strengths and weaknesses. Individuals and 
societies pencil the fine line between what is distinctive and 
extraordinary and what is peculiar and unacceptable. Prenatal 
genetic screening allows parents to make decisions for selective 
abortion. Some insist that parents should have full autonomy to 
terminate pregnancies for babies that seem inferior. Others 
argue that babies should be protected from those who would 
reject them because they do not meet an arbitrary standard. 
Genetic Therapy 
The vast majority of Americans believe couples should have 
the right to abort a seriously defective fetus. About 80% would 
terminate a pregnancy if they were told their fetus had Down's 
syndrome. A survey of parents of children with cystic fibrosis 
showed that 20% would abort for cystic fibrosis, 17% would 
abort for incurable disorders starting at age 40, and 7% for those 
starting at age 60. 12 Greater than one in 10 would abort for 
obesity and another 2% to 3% would terminate a pregnancy if 
their fetus were diagnosed to have treatable diseases like cleft 
palate or nearsightedness. Some parents even feel that the sex of 
a child is relevant. A recent study of American genetic counse-
lors concluded that a large percentage would perform prenatal 
testing for the sole purpose of sex selection.13 
How would limits be placed on selective abortion? In an 
agricultural society, genes with potential for physical deftness 
rather than intellectual prowess would be valued. For the aca-
demic, the opposite might hold. For some couples, reproductive 
decisions can center on cosmetic issues and pregnancies could 
be terminated because of straight-hair genes or lack of height. 
Ideas such as normal and disabled are rooted in shifting societal 
values; even if restrictions for abortions after prenatal diagnosis 
were legalized, the determination of these boundaries would be 
formidable. 
This analysis may seem out of place in a society that permits 
abortion on demand. And it would be pointless were it not for the 
impact of physician counsel on patient decisions. In a recent 
study, the parents whose doctors approved of an abortion for 
cystic fibrosis were nearly twice as likely to abort for cystic 
fibrosis than those parents with disapproving doctors. 14 
Well-informed, compassionate, and insightful physicians ought 
to assist patients in their own understanding of what normalcy is 
and guide them to make appropriate decisions. 
Who Should Offer Genetic Services? 
Many believe that genetic specialists should be the ones offering 
counseling and screening services. 2 Geneticists are concerned 
that most physicians are not familiar with genetic concepts and 
lack the tools to serve as effective counselors. They demand a 
minimum of graduate-level training as a prerequisite. A recent 
study found that many primary care physicians, especially those 
who are not exposed regularly to genetics, are not familiar 
-
The goal of genetic manipulation is twofold: First, to repair or 
replace defective genes in somatic or germ-line cells; and 
second, to improve the genetic makeup of the sperm, egg, or 
early products of conception to improve the attributes of descen-
dants. The former is considered correction; the latter, enhance-
ment. 
Gene therapy involves the manipulation of somatic or germ-line 
cells to alter their genetic composition. Germ-line engineering 
produces genetic changes that become permanently encoded in 
the sex cells of the person, while somatic cell alteration affects 
only the individual and should not produce inheritable changes. 
Somatic-Cell Therapy 
Somatic-cell gene therapy is a treatment of existing gene pathol-
ogy. Many clinical protocols are presently underway to offer 
therapy for individuals with adenosine deaminase deficiency 
and certain types of cancer. On the horizon are treatments for 
other diseases including Lesch-Nyhan syndrome, herpes sim-
plex, melanoma, familial cholesterolemia, and many types of 
malignancies. Previously, no effective cures had been available 
for most of these conditions. 
Somatic-cell gene therapy cannot abolish genetic disease. In 
fact, should it become widely successful, it will increase the 
number of gene carriers with homozygous disease who will face 
the certainty of passing problem genes to their children.16 This in 
turn will lead to a logarithmic increase in the need for somatic-cell 
therapy in future generations. Therefore, somatic-cell therapy 
alone is not beneficial in the long run. 
Germ-Cell Therapy 
Germ-line engineering of the human genome may become 
technically feasible within a decade. Specific techniques for the 
genomic alteration of germ cells has been demonstrated in 
animal modelsP Germ-line changes generally would be ex-
pected to affect the genetic make-up of all tissues and cells in the 
developing offspring and all subsequent generations with grave 
implications for both the individual and for society at large. 18 
Potential justification for germ-line alterations include the 
correction of genetic defects not otherwise amenable to 
somatic-cell treatment, permanent stabilization of genetic mate-
rial in offspring of high-risk mating, or the elimination of the 
need for repeated prenatal diagnosis and selective abortion in 
genetically at-risk families. 17 According to one view, a trial of 
genetic therapy would be justified only if the following condi-
tions held: 1) the risk of treatment were no greater than the risk 
of being born with the given condition or of being destroyed 
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prior to implantation (the non-treatment options); 2) no other 
treatment were available that offered a superior risk/benefit 
ratio; 3) the purely research components of the trial did not pose 
substantial risk; and 4) consent had been obtained from an 
appropriate guardian. 18 
Dr Marc Lappe, professor of health policy and economics, 
argues that since changes in the germ-line potentially affect 
others in addition to the recipient of the altered germinal tissue 
(ie, the offspring and future descendants), such experimentation 
raises novel questions of traditional research ethics. Foremost 
among these is the adequacy and acceptability of proxy consent. 
Germ-line interventions may subject at least one or probably 
two generations of future persons to experimentation before the 
phenotypic effects of the germinal change can be said to test 
outP Medicine is not an exact science. Many times patients are 
treated with well-researched FDA-approved drugs and develop 
serious side effects. Germ-line manipulation must surely be at 
least as problematic. Germ-line research presupposes direct 
experimentation on and destruction of embryos. The acceptabil-
ity of this pivots on the acceptability of killing genetically 
altered but defective embryos or allowing their creation in the 
first place.17 
Criteria to safeguard the direct genetic manipulation of the 
pre-embryo have been proposed. They include: 1) a specific 
correction of a defective gene will be made, 2) the procedure will 
not introduce any genetic errors or new genetic material that 
could have unpredictable effects in subsequent generations, and 
3) such procedures include a check to ensure that the procedure 
has been carried out as intended, before allowing the pregnancy 
to proceed. 16 
In our fast-food and microwave society, quick processes tend 
to be over-esteemed. Nature already has a way of ridding the 
genetic pool of inferior genes via spontaneous abortion and 
natural selection. We cannot be assured that scientists in their 
laboratories will be able to better this process. 
Enhancement of Normal Individuals 
Germ line interventions can promote desirable genes or de-
crease deleterious ones to produce an improved genetic profile. 17 
For many, this eugenic goal stirs memories of the forced genetic 
and ethnic cleansing attempted by Germany and the Soviet 
Union and the legislated sterilization of the disabled in the 
United States. 
Enhancement is one side of eugenics. Instead of removing bad 
genes, it hopes to improve on normal ones. As knowledge of the 
structure and function of the human genome expands, social 
pressures will mount not only to repair defects and disorders, but 
also to intervene at improving or perfecting the structure and 
function of the genome. Enhancing a child's genes, one might 
argue, is analogous to giving a child a private education, a trip 
to Europe, or plastic surgery. If parents have the right to give 
their children these other benefits, do they not also have the right 
to give them enhanced genes?9 Is the ability to pay determina-
tive, and would this not serve to widen the gap between the haves 
and the have nots? 
And as genetic enhancement becomes more frequently used, 
the cost of services may actually drop making the technology 
available for almost everyone. What then would our brave new 
world look like? 
Conclusion 
Ready or not, we are entering the age of the new genetics. 
Professional perspectives vary. Generally, geneticists are con-
cerned about improving the gene pool, lawyers are interested in 
setting legal precedence, sociologists look beyond individuals 
to consider society as a whole, and entrepreneurs drool over the 
prospects of this new industry. Who, if not doctors, will lead us 
into this new era and advocate for and protect individual patients 
and their families? 
Some physicians will remain largely ignorant or disinterested 
in these issues. Others will opt to refer their patients for genetic 
services, thus missing the opportunity to tailor-make plans for 
patients best known to them. Still others will become well-versed 
in the new genetics. They will recommend appropriate genetic 
services and expertly counsel their patients who trust them. They 
will also guide their patients in their decisions regarding screen-
ing and therapeutic options in the same manner they have guided 
their patients before. the age of gene sampling, selection and 
cure. 
Are primary care physicians prepared to lead? First, they must 
draw on the resources of the geneticists to understand the 
science; then they must look to the philosophers to appreciate 
fully the bioethics. Legal issues, societal concerns, and financial 
matters must also be appreciated. These are the caring and 
responsible physicians who will set the cadence and direction of 
our march into the new genetics. 
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